Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) selectively binds to proteolyzed collagen type I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) reduces PD L1 levels in tumor cells. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) can be used for the researches of cancer and inflammation, such as such as ovarian tumor [1] [2] [3].
In Vivo, Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (250 μg, i.p., 3 times a week for 14 or 21 days) suppresses tumor growth inΒ16F10/4T1 tumor mice models[2]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (100 μg, i.p., 1-2 times a week) shows anti-tumor effect in intraperitoneal ID8 tumor and ID8-VEGF ovarian tumor mice models[3].
In Vitro, Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (16 h) exhibits selective binding for proteolyzed collagen type I[1]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (10 μg, daily for 3 times) significantly inhibits the number of FGF-2-induced chick chorioallantoic membranes exhibiting inflammation and reduces the levels of inflammatory infiltrates[1]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (10 μg/mL, 24 h) shows no cytotoxicity in Β16F10 melanoma cells[2]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (100 μg/mL, 15 mins or 1 h) reduces PD L1 and nuclear YAP levels by a proteasome dependent mechanism in Β16F10, YUMM1.7, C32 and A375 tumor cells[2].
References:
[1]. Ames JJ, et al. Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway. J Biol Chem. 2016 Feb 5;291(6):2731-50.
[2]. Caron JM, et al. Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth. Oncol Rep. 2023 Feb;49(2):44.
[3]. Brooks, et al. Reversing Immunotherapy Resistance in Ovarian Cancer by Targeting a Novel Immune-Suppressive Factor Released by Tumor-Associated Macrophages (TAMs). Technical Report,15 Apr 2017,14 Apr 2020.
In Vivo, Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (250 μg, i.p., 3 times a week for 14 or 21 days) suppresses tumor growth inΒ16F10/4T1 tumor mice models[2]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (100 μg, i.p., 1-2 times a week) shows anti-tumor effect in intraperitoneal ID8 tumor and ID8-VEGF ovarian tumor mice models[3].
In Vitro, Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (16 h) exhibits selective binding for proteolyzed collagen type I[1]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (10 μg, daily for 3 times) significantly inhibits the number of FGF-2-induced chick chorioallantoic membranes exhibiting inflammation and reduces the levels of inflammatory infiltrates[1]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (10 μg/mL, 24 h) shows no cytotoxicity in Β16F10 melanoma cells[2]. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) (100 μg/mL, 15 mins or 1 h) reduces PD L1 and nuclear YAP levels by a proteasome dependent mechanism in Β16F10, YUMM1.7, C32 and A375 tumor cells[2].
References:
[1]. Ames JJ, et al. Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway. J Biol Chem. 2016 Feb 5;291(6):2731-50.
[2]. Caron JM, et al. Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth. Oncol Rep. 2023 Feb;49(2):44.
[3]. Brooks, et al. Reversing Immunotherapy Resistance in Ovarian Cancer by Targeting a Novel Immune-Suppressive Factor Released by Tumor-Associated Macrophages (TAMs). Technical Report,15 Apr 2017,14 Apr 2020.